Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00304200 · ClinicalTrials.gov registry record · Phase 1
Temodar and Sutent as Therapy for Melanoma
A Phase 1 study, sponsored by Northern California Melanoma Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00304200: Clinical Trial Phase 1 study, sponsored by Northern California Melanoma Center.
NCT00304200 is a Phase 1 study that was terminated before completion, run by Northern California Melanoma Center. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00304200, a Phase 1 study, was terminated before completion, sponsored by Northern California Melanoma Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is designed to evaluate the safety and appropriate dose of the combination of Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma (Phase 1). Once the safety and appropriate dose is determined, additional patients will be studied at that dose to determine if there is clinical benefit as determined by the primary end-point of progression-free survival (PFS) at 6 months and additional secondary endpoints (Phase II).
Interventions
- DRUG Temozolomide and SU11248
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Why NCT00304200 stopped before completion
NCT00304200 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which Temozolomide and SU11248 is the first listed.
NCT00304200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00304200 about?
NCT00304200 is a clinical study titled "Temodar and Sutent as Therapy for Melanoma". This study is designed to evaluate the safety and appropriate dose of the combination of Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma (Phase 1). Once the safety and appropriate dose is determined, additional patients will be studied at that dose to determi...
What is the current status of trial NCT00304200?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2006-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00304200?
The interventions under investigation include: Temozolomide and SU11248 (DRUG).
Who is sponsoring clinical trial NCT00304200?
This trial is sponsored by Northern California Melanoma Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00304200's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia